

CorMedix Inc.
Form 4
January 22, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Lefkowitz Steven W

(Last) (First) (Middle)

C/O CORMEDIX INC., 745 ROUTE
202-206, SUITE 303

(Street)

BRIDGEWATER, NJ US 08807

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
CorMedix Inc. [CRMD]

3. Date of Earliest Transaction
(Month/Day/Year)
01/17/2014

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner
☒ Officer (give title below) ☐ Other (specify
below)

Interim Chief Financial Ofcr

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, \$0.001 par value per share	01/17/2014		X	37,500 A	\$ 0.4 179,429	D	
Common Stock, \$0.001 par value per share	01/17/2014		F	5,468 (10) D	\$ 2.7431 173,961	D	
Common Stock,	01/17/2014		X	87,500 A	\$ 0.4 187,500	I ⁽¹⁾	Wade Capital

\$0.001 par value per share									Corporation Money Purchase Plan
Common Stock, \$0.001 par value per share	01/17/2014		F	12,759 (10)	D	\$ 27,431	174,741	I (1)	Wade Capital Corporation Money Purchase Plan
Common Stock, \$0.001 par value per share							10,000 (11)	I	Reporting Perons's Wife

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Stock Option (right to buy)	\$ 2.02							<u>(2)</u>	01/09/2024	Common Stock, \$0.001 par value per share	200,000
Stock Option (right to buy)	\$ 2.02							<u>(7)</u>	01/09/2024	Common Stock, \$0.001 par value per share	30,000
Swries C-3 Non-Voting Convertible	\$ 1							<u>(3)</u>	<u>(3)</u>	Common Stock, \$0.001	45,000

Preferred Stock					par value per share	
Warrant (right to purchase Common Stock)	\$ 1.25		01/08/2015	01/08/2020	Common Stock, \$0.001 par value per share	22,500
Series C-3 Non-Voting Convertible Preferred Stock	\$ 1		<u>(4)</u>	<u>(4)</u>	Common Stock, \$0.001 par value per share	30,000
Warrant (right to purchase Common Stock)	\$ 1.25		01/08/2015	01/08/2020	Common Stock, \$0.001 par value per share	15,000
Warrant (right to purchase Common Stock)	\$ 3.4375		08/20/2012	03/24/2015	Common Stock, \$0.001 par value per share	5,000
Stock Option (right to buy)	\$ 0.9		<u>(5)</u>	03/20/2023	Common Stock, \$0.001 par value per share	120,000
Stock Option (right to buy)	\$ 0.68		<u>(6)</u>	12/05/2022	Common Stock, \$0.001 par value per share	150,000
Stock Option (right to buy)	\$ 0.29		<u>(7)</u>	01/06/2022	Common Stock, \$0.001 par value per share	30,000
Stock Option (right to buy)	\$ 1.1		<u>(8)</u>	08/11/2021	Common Stock, \$0.001 par value per share	30,000
Warrant (right to	\$ 3.4375		<u>(9)</u>	03/24/2015	Common Stock,	19,500

purchase Common Stock)									\$0.001 par value per share	
Warrant (right to purchase Common Stock)	\$ 0.4	01/17/2014	X	37,500	11/13/2012	11/13/2017			Common Stock, \$0.001 par value per share	37,5
Warrant (right to purchase Common Stock)	\$ 0.4	01/17/2014	X	87,500	09/20/2012	09/20/2017			Common Stock, \$0.001 par value per share	87,5

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Lefkowitz Steven W C/O CORMEDIX INC. 745 ROUTE 202-206, SUITE 303 BRIDGEWATER, NJ US 08807	X		Interim Chief Financial Ofcr	

Signatures

Alexander M. Donalson by Power of Attorney

01/22/2014

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control).
- (2) The options vested 100% on January 10, 2014.
On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, \$0.001 par value per share at a conversion price of \$1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of \$1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of \$10.00 per share for each share of Series C-3 Preferred Stock.
- (3) On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, \$0.001 par value per share at a conversion price of \$1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of \$1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of \$10.00 per share for each share of Series C-3 Preferred Stock.
- (4) These options vest quarterly over two years beginning June 13, 2013.
- (5)

Edgar Filing: CorMedix Inc. - Form 4

- (6) These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
- (7) The options vest in full on the first anniversary of the date of grant.
- (8) The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
- (9) The warrants were issued as part of the Company's initial public offering in March 2010 and were exercisable beginning six months after the effective date of the Company's registration statement related thereto.
- (10) Does not represent a sale in the market; represents the cashless exercise through the forfeiture of shares to the Issuer to pay the purchase price of the shares acquired upon conversion of the warrant.
- (11) The last report for the reporting person mistakenly entered this amount as 1,000 shares; however, the correct amount is 10,000 shares as had been previously reported.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.